Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects - Wikidata - awgldk - TriplyDB

Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects

Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects

http://www.wikidata.org/entity/Q34632230

about

Strategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant bacterial infections Healthcare-associated infections, infection control and the potential of new antibiotics in development in the USA New trends in aminoglycosides use.Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin.Investigational antimicrobial agents of 2013.Plazomicin: an investigational therapy for the treatment of urinary tract infections.Activity of plazomicin (ACHN-490) against MDR clinical isolates of Klebsiella pneumoniae, Escherichia coli, and Enterobacter spp. from Athens, Greece.Pipeline of Known Chemical Classes of Antibiotics.A review of patents (2011-2015) towards combating resistance to and toxicity of aminoglycosides New antibiotic agents in the pipeline and how they can help overcome microbial resistance.New and alternative approaches to tackling antibiotic resistance.In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.Antibiotics in development targeting protein synthesis.Aminoglycoside therapy in infectious diseases.Prospects for circumventing aminoglycoside kinase mediated antibiotic resistance.Current strategies for the treatment of complicated intraabdominal infections.Neutrophil gelatinase associated lipocalin in acute kidney injury.Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens.Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance.Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia.The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?Efficacy and Safety of Plazomicin Compared with Levofloxacin in the Treatment of Complicated Urinary Tract Infection and Acute Pyelonephritis: A Multicenter, Randomized, Double-Blind, Phase 2 Study.

P2860

Q26859978-589238BF-5601-4560-9F50-75D5EC946B18 Q26995305-170729A4-30DE-449F-9A44-0DF14F9BB585 Q33951177-8C9B23F2-9005-4A25-A9BE-511C9B981539 Q34269044-2A143D4A-D1CC-47E4-A714-7675514B3B3D Q34375204-8AE948AB-6E7E-4F1D-A04B-6D05D871CB08 Q34673393-B6297156-0B80-4F3C-962A-3A2755A9B74F Q36107990-7D4E4CE3-B4AD-406A-893C-591CF6BFADDE Q36683409-4904D98C-99F8-49CB-8A8E-67815604ACFF Q36726249-F71ED991-0F72-4A87-990E-3E8B1E56DCB9 Q36845895-51BA3070-1527-4A35-88EB-3638631C72EA Q37372123-4CF1318E-ABEE-4307-B048-44CCB17561B8 Q37712980-9AEA9598-791E-486C-8410-2ADFB143CF3B Q37970724-0943252E-DD19-4FB7-9CEB-B64C9CBB7C1A Q38112810-31708CF9-8E80-4671-8EEF-2D69A5D5F7C6 Q38117380-673AC945-F573-49D4-B3B1-94B087B121B0 Q38123247-4C2CC8E4-69B3-4F49-81AA-CC0B3169D424 Q38160639-1AFF6038-D6D4-4973-9838-CD92768EEC86 Q38262205-D44ABC30-4E3B-4F83-8C71-E27163E861BF Q38672016-81893AB5-E9A9-424C-A8C1-C07F3DA5A61E Q38783043-4181F3D6-BA02-496F-9251-314277D5754F Q38892589-B4D28F36-CC15-4000-A33E-7E1FA4A32F59 Q49598865-1981C993-2D80-4C17-BF15-87AD48D21B6E

P2860

Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects

http://www.wikidata.org/entity/Q34632230

description

2011 nî lūn-bûn

@nan

2011 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Pharmacokinetics and safety of ...... ravenously in healthy subjects

@ast

Pharmacokinetics and safety of ...... ravenously in healthy subjects

@en

Pharmacokinetics and safety of ...... ravenously in healthy subjects

@nl

type

label

Pharmacokinetics and safety of ...... ravenously in healthy subjects

@ast

Pharmacokinetics and safety of ...... ravenously in healthy subjects

@en

Pharmacokinetics and safety of ...... ravenously in healthy subjects

@nl

prefLabel

Pharmacokinetics and safety of ...... ravenously in healthy subjects

@ast

Pharmacokinetics and safety of ...... ravenously in healthy subjects

@en

Pharmacokinetics and safety of ...... ravenously in healthy subjects

@nl

P1433

Q34632230-36F13E9E-C530-4662-B5C8-EE020746CFDC

P1476

Q34632230-43B585EF-49A7-49FB-99CE-99D8744D6CC2

P2093

Q34632230-1DAE53F2-F0C2-4693-B42A-BE25D520C120

Q34632230-2D49E039-4165-4084-907E-7E2E95A61B04

Q34632230-447D0E3E-1DC4-4F8F-A25F-DB69726C9491

Q34632230-7A072198-AEAD-469A-8381-6D15534F6B11

Q34632230-820D8FCA-A5B5-423C-AEF1-A257964A9EB4

Q34632230-EE1CA644-9E52-4A0A-A83D-816896F2F40F

Q34632230-EF0107E1-11D0-4D43-80E1-588E233508F5

P2860

Q34632230-131E8144-F5CF-47CC-8FB1-99D68353FB7F

Q34632230-1873427E-E9A7-4B7C-9674-7E3FAA408C77

Q34632230-1B54FFDB-195A-4E46-9793-41460A57D06C

Q34632230-1E08543C-ED08-48E3-A998-07392210DA54

Q34632230-28FE7B5F-EC2D-42C8-853F-D2813227110E

Q34632230-33F01AD5-0FA4-467E-BB7D-5F8915C631FB

Q34632230-431C908B-20DE-4870-84A9-E9F4289B1227

Q34632230-445FE433-EDBC-4FBD-9D62-49ED14EFF2ED

Q34632230-73FF4E7E-660F-43AD-A3EB-1A0FB6F70179

Q34632230-78E13798-D47D-4E86-B2AD-401AC1639968

P304

Q34632230-B050DF5A-930B-4021-BA3F-9EF4F60007B3

P31

Q34632230-88CCB1A7-0F56-4547-9CA6-9E4EFEFE2293

P356

Q34632230-C31FB668-D1B7-428F-B74C-AEE72C2DA65D

P407

Q34632230-64DBBD07-A8D6-4A15-BCA2-E1D409357D04

P433

Q34632230-93B6EDE5-4FD0-41C0-86BE-880D488FAD56

P478

Q34632230-4C47E47F-93A9-493F-8C86-6B453E762B54

P577

Q34632230-F15A05F4-05B2-49ED-923A-4467A67FD28E

P698

Q34632230-20107E22-17BC-44F8-9B25-9E25BE9546EE

P932

Q34632230-87C7A3B9-28F6-442C-A13E-C1416291670A

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacokinetics and safety of ...... ravenously in healthy subjects

@en

P2093

Carter D Brooks

http://www.w3.org/2001/XMLSchema#string

Don Young

http://www.w3.org/2001/XMLSchema#string

Jon B Bruss

http://www.w3.org/2001/XMLSchema#string

Kenneth J Tack

http://www.w3.org/2001/XMLSchema#string

Marie T Borin

http://www.w3.org/2001/XMLSchema#string

Nancy A Havrilla

http://www.w3.org/2001/XMLSchema#string

Robert T Cass

http://www.w3.org/2001/XMLSchema#string

P2860

Prediction of creatinine clearance from serum creatinine

Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity

Synthesis and spectrum of the neoglycoside ACHN-490

Do we still need the aminoglycosides?

Back to the future: using aminoglycosides again and how to dose them optimally.

ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates.

Combating evolution with intelligent design: the neoglycoside ACHN-490.

Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.

Comparative study with enoxacin and netilmicin in a pharmacodynamic model to determine importance of ratio of antibiotic peak concentration to MIC for bactericidal activity and emergence of resistance.

Kill kinetics and regrowth patterns of Escherichia coli exposed to gentamicin concentration-time profiles simulating in vivo bolus and infusion dosing.

P304

5874-5880

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.00624-11

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2011-09-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21911572

http://www.w3.org/2001/XMLSchema#string

P932

3232771

http://www.w3.org/2001/XMLSchema#string